(Boursier.com) — Carried away yesterday by the market decline, Ipsen stands out at the end of the morning with a share which advances by 3% to 124.6 euros. The laboratory is being sought after the announcement of good news from the United States. Local regulatory authorities (Food and Drug Administration) have granted approval, via an accelerated procedure, to Iqirvo (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA). ) in adults with an inadequate response to UDCA, or as monotherapy in patients intolerant to UDCA. Iqirvo can be prescribed now in the United States for eligible patients.
PBC is a rare autoimmune cholestatic liver disease in which an accumulation of bile and toxins (cholestasis) and chronic inflammation cause irreversible fibrosis (scarring) of the liver and destruction of the bile ducts. Around 100,000 people are affected in the United States, the majority of them women.
©2024 Boursier.com